journal article·2025-05

New NIR‐Activated Organic Molecule‐Based Nanocomposite as an Efficient Sensitizer for Photothermal and Photodynamic Therapy of Cancer

Ming‐Hsin Liu, Zhen‐Jie Gao, Wei‐Yung Huang, Chi‐Hung Hsiao, Vincent Chen, Lee‐Jene Lai, Zi‐Jing Lin, Mo D.‐S. Hua, Chia‐Chun Hsieh, Er‐Yuan Chuang, Jiashing Yu, Ken‐Tsung Wong

Advanced Healthcare Materials· Volume 14· Issue 13
Publisher page

Abstract

Abstract Acceptor–donor–acceptor (A–D–A)‐configured molecules with coplanar dithieno[2,3‐d:2′,3′‐d’]thieno[3,2‐b:3′,2′‐b’]dipyrrole (DTPT) as the core are promising organic semiconductor materials utilized in organic photovoltaic devices owing to their efficient charge transportation capabilities. In addition to optoelectronic applications, they are potential in photothermal and photodynamic applications due to their light‐absorption properties. This study evaluates the utilization of DTPT‐based fused‐ring‐conjugated small molecules with strong near‐infrared (NIR) absorption as stable organic photosensitizers for phototherapy by forming nanoparticles (NPs) with D‐α‐tocopherol polyethylene glycol 1000 succinate (TPGS). Among them, NPs prepared from the 2‐(3‐cyano‐4,5,5‐trimethylfuran‐2(5H)‐ylidene)malononitrile (TCF) end‐capping DTPT‐centered molecule, DTPTTCF, exhibit low cytotoxicity, enhance photothermal conversion efficiency and superior photodynamic activity. In vitro and in vivo experiments demonstrate the remarkable anticancer efficacy of DTPTTCF@TPGS NPs that can effectively suppress cancer cell proliferation under 808 nm laser treatment. Additionally, soft X‐ray tomography (SXT) is employed as a high‐resolution tool to observe intracellular variations that reveal distinct vacuolization in the NPs + Laser treated group. These observations highlight that the DTPTTCF@TPGS NPs cause significant damage to cancer cells under NIR irradiation. Furthermore, in vivo, experiments demonstrate the apoptosis of cancer cells within tumor tissues and the effective elimination of tumors upon NIR irradiation of DTPTTCF@TPGS NPs treated mice. This work manifests the potential application of the DTPT‐cored A–D–A‐type molecule as an advanced agent for tumor phototherapy with enhanced efficacy and selectivity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Luminescence and Fluorescent Materials · Photoacoustic and Ultrasonic Imaging

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering National Taiwan University Taipei 10617 Taiwan

Department of Chemistry National Taiwan University Taipei 10617 Taiwan

Graduate Institute of Biomedical Materials and Tissue Engineering Taipei Medical University Taipei 11031 Taiwan

Experimental Facility Division National Synchrotron Radiation Research Center Hsinchu 300092 Taiwan

Institute of Atomic and Molecular Science Academia Sinica Taipei 10617 Taiwan

Funding

National Synchrotron Radiation Research Center · Ministry of Education · National Science and Technology Council

References (50)

Show source-provided references
1. 10.1039/C8CS00001H10.1039/C8CS00001H ↗
2. 10.1021/acs.accounts.9b0056910.1021/acs.accounts.9b00569 ↗
3. 10.1039/D1CS00056J10.1039/D1CS00056J ↗
4. 10.1016/j.cej.2019.12247210.1016/j.cej.2019.122472 ↗
5. 10.1016/j.biomaterials.2019.11928210.1016/j.biomaterials.2019.119282 ↗
6. 10.1016/j.ccr.2023.21556010.1016/j.ccr.2023.215560 ↗
7. 10.1016/j.ccr.2020.21354810.1016/j.ccr.2020.213548 ↗
8. 10.1039/D0QM00617C10.1039/D0QM00617C ↗
9. 10.1002/adhm.20230442110.1002/adhm.202304421 ↗
10. 10.1002/adhm.20230456410.1002/adhm.202304564 ↗
11. 10.1002/anie.20241151410.1002/anie.202411514 ↗
12. 10.1021/acs.biomac.8b0046010.1021/acs.biomac.8b00460 ↗
13. 10.1002/smll.20210452110.1002/smll.202104521 ↗
14. 10.1016/j.actbio.2022.04.04410.1016/j.actbio.2022.04.044 ↗
15. 10.1039/C8CS00618K10.1039/C8CS00618K ↗
16. 10.1038/s41578-019-0108-110.1038/s41578-019-0108-1 ↗
17. 10.1021/acs.chemrev.3c0015910.1021/acs.chemrev.3c00159 ↗
18. 10.1021/acs.chemrev.1c0055310.1021/acs.chemrev.1c00553 ↗
19. 10.1002/anie.20220460410.1002/anie.202204604 ↗
20. 10.1016/S1040-8428(01)00179-210.1016/S1040-8428(01)00179-2 ↗
21. 10.1016/j.ccr.2024.21592210.1016/j.ccr.2024.215922 ↗
22. 10.1002/anie.20190628810.1002/anie.201906288 ↗
23. 10.1002/adma.20190499710.1002/adma.201904997 ↗
24. 10.1021/acsanm.4c0089010.1021/acsanm.4c00890 ↗
25. 10.1016/j.ccr.2022.21448610.1016/j.ccr.2022.214486 ↗
26. 10.1002/adhm.20240198110.1002/adhm.202401981 ↗
27. 10.1002/cmdc.20210013810.1002/cmdc.202100138 ↗
28. 10.1021/acsmaterialslett.0c0026310.1021/acsmaterialslett.0c00263 ↗
29. 10.1002/adfm.20200254610.1002/adfm.202002546 ↗
30. 10.1002/bio.470810.1002/bio.4708 ↗
31. 10.1039/D4TB00187G10.1039/D4TB00187G ↗
32. 10.1002/adma.20200347110.1002/adma.202003471 ↗
33. 10.1002/adma.20220822910.1002/adma.202208229 ↗
34. 10.1002/anie.20230347610.1002/anie.202303476 ↗
35. 10.1021/acs.nanolett.3c0011910.1021/acs.nanolett.3c00119 ↗
36. 10.1021/acs.analchem.2c0307310.1021/acs.analchem.2c03073 ↗
37. Xiao H. · Adv. Healthcare Mater. · 2023
38. 10.1007/s40843-022-2143-210.1007/s40843-022-2143-2 ↗
39. 10.1016/j.jconrel.2014.03.00910.1016/j.jconrel.2014.03.009 ↗
40. 10.1016/j.onano.2022.10003610.1016/j.onano.2022.100036 ↗
41. 10.1016/j.ijpharm.2020.12018410.1016/j.ijpharm.2020.120184 ↗
42. 10.1080/10717544.2023.218383010.1080/10717544.2023.2183830 ↗
43. 10.3390/pharmaceutics1406123210.3390/pharmaceutics14061232 ↗
44. 10.1021/ja302320c10.1021/ja302320c ↗
45. 10.1002/adfm.20231281910.1002/adfm.202312819 ↗
46. 10.1016/j.orgel.2015.01.00510.1016/j.orgel.2015.01.005 ↗
47. 10.1002/adma.20140244810.1002/adma.201402448 ↗
48. 10.1021/ol300887t10.1021/ol300887t ↗
49. 10.1039/C4TA06705C10.1039/C4TA06705C ↗
50. 10.1021/acsnano.0c0276710.1021/acsnano.0c02767 ↗